{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-023222","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.179806+00:00","generated_at":"2026-05-15T07:49:08.835941+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Vanda Pharmaceuticals General Counsel Timothy Williams resigns, effective Apr 10, 2026","bullets":["Timothy Williams resigns as SVP, General Counsel and Secretary, effective April 10, 2026.","No successor or interim replacement announced; search process not disclosed.","Resignation is to pursue other endeavors; no conflict or disagreement noted."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-023222","json":"https://secwatch.observer/filing/0001628280-26-023222.json","markdown":"https://secwatch.observer/filing/0001628280-26-023222.md","text":"https://secwatch.observer/filing/0001628280-26-023222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/0001628280-26-023222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/vnda-20260329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:49:08.835941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}